10x Genomics, Inc. (TXG)

10x Genomics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	624.66	610.79	618.73	516.41	490.49	298.85
Revenue Growth (YoY)	-0.13%	-1.28%	19.81%	5.28%	64.13%	21.54%
Cost of Revenue	197.65	196	209.41	120.09	74.09	58.47
Gross Profit	427.01	414.78	409.31	396.32	416.4	240.38
Selling, General & Admin	348.3	343.24	343.33	295.8	257.56	202.33
Research & Development	260.31	264	265.73	264.27	211.75	123.38
Operating Expenses	608.6	607.24	609.06	560.07	469.31	325.7
Operating Income	-181.59	-192.46	-199.75	-163.74	-52.91	-85.32
Interest Expense	-0	-0	-0.03	-0.48	-0.87	-1.68
Interest & Investment Income	17.4	18.45	16.91	6.65	0.21	1.53
Currency Exchange Gain (Loss)	-4.6	-2.1	1.2	0.2	-0.9	1.3
Other Non Operating Income (Expenses)	6.19	0.52	0.21	-0.4	0.1	0.04
EBT Excluding Unusual Items	-162.6	-175.6	-181.47	-157.77	-54.38	-84.14
Merger & Restructuring Charges	-	-	-	-4.2	-	-
Gain (Loss) on Sale of Investments	-0	-0	-1.72	-	-	-
Asset Writedown	-	-2.1	-4.6	-	-	-
Legal Settlements	9.2	-	-	-	0.66	-1.27
Other Unusual Items	-	-	-	-	-	-1.52
Pretax Income	-153.4	-177.7	-248.76	-161.97	-53.72	-534.48
Income Tax Expense	3.63	4.93	6.34	4.03	4.51	8.26
Net Income	-157.04	-182.63	-255.1	-166	-58.22	-542.73
Net Income to Common	-157.04	-182.63	-255.1	-166	-58.22	-542.73
Shares Outstanding (Basic)	121	120	117	114	110	101
Shares Outstanding (Diluted)	121	120	117	114	110	101
Shares Change (YoY)	2.66%	2.80%	2.90%	3.18%	9.09%	158.76%
EPS (Basic)	-1.30	-1.52	-2.18	-1.46	-0.53	-5.37
EPS (Diluted)	-1.30	-1.52	-2.18	-1.46	-0.53	-5.37
Free Cash Flow	45.36	-5.73	-63.8	-165.27	-122.65	-254.56
Free Cash Flow Per Share	0.37	-0.05	-0.55	-1.45	-1.11	-2.52
Gross Margin	68.36%	67.91%	66.15%	76.75%	84.89%	80.44%
Operating Margin	-29.07%	-31.51%	-32.28%	-31.71%	-10.79%	-28.55%
Profit Margin	-25.14%	-29.90%	-41.23%	-32.15%	-11.87%	-181.61%
Free Cash Flow Margin	7.26%	-0.94%	-10.31%	-32.00%	-25.01%	-85.18%
EBITDA	-146.88	-156.58	-164.24	-138.38	-31.8	-71.31
EBITDA Margin	-23.51%	-25.64%	-26.54%	-26.80%	-6.48%	-23.86%
D&A For EBITDA	34.71	35.88	35.51	25.37	21.12	14.01
EBIT	-181.59	-192.46	-199.75	-163.74	-52.91	-85.32
EBIT Margin	-29.07%	-31.51%	-32.28%	-31.71%	-10.79%	-28.55%
Advertising Expenses	-	3.9	3.3	3.7	4.7	1.9

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q